Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum
Abstract Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order t...
Gespeichert in:
| Veröffentlicht in: | Brain research 2012-11, Vol.1483, p.31-38 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | |
| container_start_page | 31 |
| container_title | Brain research |
| container_volume | 1483 |
| creator | Yarosh, Haley L Angulo, Jesus A |
| description | Abstract Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order to better understand the role of the striatal neuropeptides on the METH-induced production of NO, we used agonists and antagonists of the NPY (Y1R and Y2R) receptors infused via intrastriatal microinjection followed by a bolus of METH (30 mg/kg, ip) and measured 3-NT immunofluorescence, an indirect index of NO production. One striatum received pharmacological agent while the contralateral striatum received aCSF and served as control. NPY receptor agonists dose dependently attenuated the METH-induced production of striatal 3-NT. Conversely, NPY receptor antagonists had the opposite effect. Moreover, METH induced the accumulation of cyclic GMP and activated caspase-3 in approximately 18% of striatal neurons, a phenomenon that was attenuated by pre-treatment with NPY2 receptor agonist. Lastly, METH increased the levels of striatal preproneuropeptide Y mRNA nearly five-fold 16 h after injection as determined by RT-PCR, suggesting increased utilization of the neuropeptide. In conclusion, NPY inhibits the METH-induced production of NO in striatal tissue. Consequently, production of this second messenger induces the accumulation of cyclic GMP and activated caspase-3 in some striatal neurons, an event that may precede the apoptosis of some striatal neurons. |
| doi_str_mv | 10.1016/j.brainres.2012.09.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4012334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S000689931201476X</els_id><sourcerecordid>1125228762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c589t-af76acdf0f6e258f9c366d2e47baf74cfffdaa063a9afb3ccfc50153d41c25283</originalsourceid><addsrcrecordid>eNqFUk1v1DAQtRCILoW_UPmCxCWpP7Le5FKBqgKVijgAEpwsxx6zXhI72E7F_nscdls-Lpwsa95782beIHRGSU0JFee7uo_K-QipZoSymnQ1ofwBWtF2wyrBGvIQrQghomq7jp-gJyntypfzjjxGJ4x1LVu33QrZd8HMg8oueBwsHiFv1ThtIavReaicN7MGg73L0WkcfjgDeIqFo39R-j32MMcwwZSX0hfsPM5bwOMcCx-nQlN5Hp-iR1YNCZ4d31P06fXVx8u31c37N9eXr24qXdzkStmNUNpYYgUUf7bTXAjDoNn0pdRoa61RigiuOmV7rrXVa0LX3DRUszVr-Sm6OOhOcz-C0eBzVIOcohtV3MugnPy74t1Wfg23silL5LwpAi-OAjF8nyFlObqkYRiUhzAnSWnpw9qNYAUqDlAdQ0oR7H0bSuQSktzJu5DkEpIknSwhFeLZnybvaXepFMDzI0AlrQYbldcu_caJRjSMLNO-POCgrPTWQZRJO_AlMBdBZ2mC-7-Xi38k9OC8K12_wR7SLszRl8Aklalw5IflpJaLokWk2YjP_Cf9I804</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1125228762</pqid></control><display><type>article</type><title>Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yarosh, Haley L ; Angulo, Jesus A</creator><creatorcontrib>Yarosh, Haley L ; Angulo, Jesus A</creatorcontrib><description>Abstract Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order to better understand the role of the striatal neuropeptides on the METH-induced production of NO, we used agonists and antagonists of the NPY (Y1R and Y2R) receptors infused via intrastriatal microinjection followed by a bolus of METH (30 mg/kg, ip) and measured 3-NT immunofluorescence, an indirect index of NO production. One striatum received pharmacological agent while the contralateral striatum received aCSF and served as control. NPY receptor agonists dose dependently attenuated the METH-induced production of striatal 3-NT. Conversely, NPY receptor antagonists had the opposite effect. Moreover, METH induced the accumulation of cyclic GMP and activated caspase-3 in approximately 18% of striatal neurons, a phenomenon that was attenuated by pre-treatment with NPY2 receptor agonist. Lastly, METH increased the levels of striatal preproneuropeptide Y mRNA nearly five-fold 16 h after injection as determined by RT-PCR, suggesting increased utilization of the neuropeptide. In conclusion, NPY inhibits the METH-induced production of NO in striatal tissue. Consequently, production of this second messenger induces the accumulation of cyclic GMP and activated caspase-3 in some striatal neurons, an event that may precede the apoptosis of some striatal neurons.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2012.09.013</identifier><identifier>PMID: 22982589</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis of Variance ; Animals ; Antagonists ; Apoptosis ; Arginine - analogs & derivatives ; Arginine - pharmacology ; Biological and medical sciences ; Brain ; Caspase 3 - metabolism ; Caspase-3 ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Cyclic GMP ; Cyclic GMP - metabolism ; Drug Interactions ; Immunofluorescence ; Male ; Medical sciences ; Methamphetamine ; Methamphetamine - pharmacology ; Mice ; Mice, Inbred ICR ; Microinjection ; Microinjections ; mRNA ; Neostriatum ; Neurology ; Neurons ; Neuropeptide Y ; Neuropeptide Y - agonists ; Neuropeptide Y - antagonists & inhibitors ; Neuropeptide Y - genetics ; Neuropeptide Y - metabolism ; Neuropeptide Y - pharmacology ; Neuropharmacology ; Nitric oxide ; Nitric Oxide Synthase Type II - metabolism ; Peptides - pharmacology ; Pharmacology. Drug treatments ; Polymerase chain reaction ; Protein Precursors - genetics ; Protein Precursors - metabolism ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Receptors, Neuropeptide Y - agonists ; Receptors, Neuropeptide Y - antagonists & inhibitors ; RNA, Messenger - metabolism ; Second messengers ; Stimulants ; Striatum ; Substance P ; Tyrosine - analogs & derivatives ; Tyrosine - metabolism</subject><ispartof>Brain research, 2012-11, Vol.1483, p.31-38</ispartof><rights>Elsevier B.V.</rights><rights>2012 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><rights>2012 Elsevier B.V. All rights reserved. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c589t-af76acdf0f6e258f9c366d2e47baf74cfffdaa063a9afb3ccfc50153d41c25283</citedby><cites>FETCH-LOGICAL-c589t-af76acdf0f6e258f9c366d2e47baf74cfffdaa063a9afb3ccfc50153d41c25283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000689931201476X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26464208$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22982589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yarosh, Haley L</creatorcontrib><creatorcontrib>Angulo, Jesus A</creatorcontrib><title>Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Abstract Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order to better understand the role of the striatal neuropeptides on the METH-induced production of NO, we used agonists and antagonists of the NPY (Y1R and Y2R) receptors infused via intrastriatal microinjection followed by a bolus of METH (30 mg/kg, ip) and measured 3-NT immunofluorescence, an indirect index of NO production. One striatum received pharmacological agent while the contralateral striatum received aCSF and served as control. NPY receptor agonists dose dependently attenuated the METH-induced production of striatal 3-NT. Conversely, NPY receptor antagonists had the opposite effect. Moreover, METH induced the accumulation of cyclic GMP and activated caspase-3 in approximately 18% of striatal neurons, a phenomenon that was attenuated by pre-treatment with NPY2 receptor agonist. Lastly, METH increased the levels of striatal preproneuropeptide Y mRNA nearly five-fold 16 h after injection as determined by RT-PCR, suggesting increased utilization of the neuropeptide. In conclusion, NPY inhibits the METH-induced production of NO in striatal tissue. Consequently, production of this second messenger induces the accumulation of cyclic GMP and activated caspase-3 in some striatal neurons, an event that may precede the apoptosis of some striatal neurons.</description><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Antagonists</subject><subject>Apoptosis</subject><subject>Arginine - analogs & derivatives</subject><subject>Arginine - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Brain</subject><subject>Caspase 3 - metabolism</subject><subject>Caspase-3</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Cyclic GMP</subject><subject>Cyclic GMP - metabolism</subject><subject>Drug Interactions</subject><subject>Immunofluorescence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methamphetamine</subject><subject>Methamphetamine - pharmacology</subject><subject>Mice</subject><subject>Mice, Inbred ICR</subject><subject>Microinjection</subject><subject>Microinjections</subject><subject>mRNA</subject><subject>Neostriatum</subject><subject>Neurology</subject><subject>Neurons</subject><subject>Neuropeptide Y</subject><subject>Neuropeptide Y - agonists</subject><subject>Neuropeptide Y - antagonists & inhibitors</subject><subject>Neuropeptide Y - genetics</subject><subject>Neuropeptide Y - metabolism</subject><subject>Neuropeptide Y - pharmacology</subject><subject>Neuropharmacology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Peptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase chain reaction</subject><subject>Protein Precursors - genetics</subject><subject>Protein Precursors - metabolism</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Receptors, Neuropeptide Y - agonists</subject><subject>Receptors, Neuropeptide Y - antagonists & inhibitors</subject><subject>RNA, Messenger - metabolism</subject><subject>Second messengers</subject><subject>Stimulants</subject><subject>Striatum</subject><subject>Substance P</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - metabolism</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAQtRCILoW_UPmCxCWpP7Le5FKBqgKVijgAEpwsxx6zXhI72E7F_nscdls-Lpwsa95782beIHRGSU0JFee7uo_K-QipZoSymnQ1ofwBWtF2wyrBGvIQrQghomq7jp-gJyntypfzjjxGJ4x1LVu33QrZd8HMg8oueBwsHiFv1ThtIavReaicN7MGg73L0WkcfjgDeIqFo39R-j32MMcwwZSX0hfsPM5bwOMcCx-nQlN5Hp-iR1YNCZ4d31P06fXVx8u31c37N9eXr24qXdzkStmNUNpYYgUUf7bTXAjDoNn0pdRoa61RigiuOmV7rrXVa0LX3DRUszVr-Sm6OOhOcz-C0eBzVIOcohtV3MugnPy74t1Wfg23silL5LwpAi-OAjF8nyFlObqkYRiUhzAnSWnpw9qNYAUqDlAdQ0oR7H0bSuQSktzJu5DkEpIknSwhFeLZnybvaXepFMDzI0AlrQYbldcu_caJRjSMLNO-POCgrPTWQZRJO_AlMBdBZ2mC-7-Xi38k9OC8K12_wR7SLszRl8Aklalw5IflpJaLokWk2YjP_Cf9I804</recordid><startdate>20121105</startdate><enddate>20121105</enddate><creator>Yarosh, Haley L</creator><creator>Angulo, Jesus A</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20121105</creationdate><title>Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum</title><author>Yarosh, Haley L ; Angulo, Jesus A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c589t-af76acdf0f6e258f9c366d2e47baf74cfffdaa063a9afb3ccfc50153d41c25283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Antagonists</topic><topic>Apoptosis</topic><topic>Arginine - analogs & derivatives</topic><topic>Arginine - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Brain</topic><topic>Caspase 3 - metabolism</topic><topic>Caspase-3</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Cyclic GMP</topic><topic>Cyclic GMP - metabolism</topic><topic>Drug Interactions</topic><topic>Immunofluorescence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methamphetamine</topic><topic>Methamphetamine - pharmacology</topic><topic>Mice</topic><topic>Mice, Inbred ICR</topic><topic>Microinjection</topic><topic>Microinjections</topic><topic>mRNA</topic><topic>Neostriatum</topic><topic>Neurology</topic><topic>Neurons</topic><topic>Neuropeptide Y</topic><topic>Neuropeptide Y - agonists</topic><topic>Neuropeptide Y - antagonists & inhibitors</topic><topic>Neuropeptide Y - genetics</topic><topic>Neuropeptide Y - metabolism</topic><topic>Neuropeptide Y - pharmacology</topic><topic>Neuropharmacology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Peptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase chain reaction</topic><topic>Protein Precursors - genetics</topic><topic>Protein Precursors - metabolism</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Receptors, Neuropeptide Y - agonists</topic><topic>Receptors, Neuropeptide Y - antagonists & inhibitors</topic><topic>RNA, Messenger - metabolism</topic><topic>Second messengers</topic><topic>Stimulants</topic><topic>Striatum</topic><topic>Substance P</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yarosh, Haley L</creatorcontrib><creatorcontrib>Angulo, Jesus A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yarosh, Haley L</au><au>Angulo, Jesus A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2012-11-05</date><risdate>2012</risdate><volume>1483</volume><spage>31</spage><epage>38</epage><pages>31-38</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Abstract Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order to better understand the role of the striatal neuropeptides on the METH-induced production of NO, we used agonists and antagonists of the NPY (Y1R and Y2R) receptors infused via intrastriatal microinjection followed by a bolus of METH (30 mg/kg, ip) and measured 3-NT immunofluorescence, an indirect index of NO production. One striatum received pharmacological agent while the contralateral striatum received aCSF and served as control. NPY receptor agonists dose dependently attenuated the METH-induced production of striatal 3-NT. Conversely, NPY receptor antagonists had the opposite effect. Moreover, METH induced the accumulation of cyclic GMP and activated caspase-3 in approximately 18% of striatal neurons, a phenomenon that was attenuated by pre-treatment with NPY2 receptor agonist. Lastly, METH increased the levels of striatal preproneuropeptide Y mRNA nearly five-fold 16 h after injection as determined by RT-PCR, suggesting increased utilization of the neuropeptide. In conclusion, NPY inhibits the METH-induced production of NO in striatal tissue. Consequently, production of this second messenger induces the accumulation of cyclic GMP and activated caspase-3 in some striatal neurons, an event that may precede the apoptosis of some striatal neurons.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>22982589</pmid><doi>10.1016/j.brainres.2012.09.013</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-8993 |
| ispartof | Brain research, 2012-11, Vol.1483, p.31-38 |
| issn | 0006-8993 1872-6240 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4012334 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analysis of Variance Animals Antagonists Apoptosis Arginine - analogs & derivatives Arginine - pharmacology Biological and medical sciences Brain Caspase 3 - metabolism Caspase-3 Corpus Striatum - drug effects Corpus Striatum - metabolism Cyclic GMP Cyclic GMP - metabolism Drug Interactions Immunofluorescence Male Medical sciences Methamphetamine Methamphetamine - pharmacology Mice Mice, Inbred ICR Microinjection Microinjections mRNA Neostriatum Neurology Neurons Neuropeptide Y Neuropeptide Y - agonists Neuropeptide Y - antagonists & inhibitors Neuropeptide Y - genetics Neuropeptide Y - metabolism Neuropeptide Y - pharmacology Neuropharmacology Nitric oxide Nitric Oxide Synthase Type II - metabolism Peptides - pharmacology Pharmacology. Drug treatments Polymerase chain reaction Protein Precursors - genetics Protein Precursors - metabolism Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Receptors, Neuropeptide Y - agonists Receptors, Neuropeptide Y - antagonists & inhibitors RNA, Messenger - metabolism Second messengers Stimulants Striatum Substance P Tyrosine - analogs & derivatives Tyrosine - metabolism |
| title | Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T22%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modulation%20of%20methamphetamine-induced%20nitric%20oxide%20production%20by%20neuropeptide%20Y%20in%20the%20murine%20striatum&rft.jtitle=Brain%20research&rft.au=Yarosh,%20Haley%20L&rft.date=2012-11-05&rft.volume=1483&rft.spage=31&rft.epage=38&rft.pages=31-38&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/j.brainres.2012.09.013&rft_dat=%3Cproquest_pubme%3E1125228762%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1125228762&rft_id=info:pmid/22982589&rft_els_id=1_s2_0_S000689931201476X&rfr_iscdi=true |